Therapy Areas: Diabetes
vTv Therapeutics Touts Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes
7 June 2019 - - US-based clinical-stage biopharmaceutical company vTv Therapeutics Inc. (NASDAQ: VTVT) has received positive results from the primary analysis of Part 1 of the Phase 2 Simplici-T1 trial assessing the liver-selective glucokinase activator TTP399 in adult patients with type 1 diabetes, the company said.
In this double-blind, placebo-controlled 12-week trial, the baseline mean HbA1c for the groups treated with TTP399 and placebo was 7.3% and 7.4%, respectively.
Patients treated with TTP399 showed a statistically significant mean reduction in HbA1c of 0.6% at 12 weeks, while the group treated with placebo showed a mean increase in HbA1c of 0.1%, resulting in a mean difference of 0.7% in the TTP399 group relative to the placebo group (p=0.03).
At the same time, trends toward decreased insulin usage were observed in the group treated with TTP399.
Patients in this study received insulin adjustments to optimise glucose levels.
As a result, the primary analysis included a responder analysis in which a 'treatment responder' was defined as a patient who had a decrease in HbA1c at Week 12, no abnormal lactate or ketones detected in blood or urine during the study, and no increased time in Level 2 hypoglycemia (blood glucose
Login
Username:

Password: